An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

Researchers excluded participants who had other chronic liver problems besides nonalcoholic fatty liver disease ... treatment modalities. The study in the NEJM showing possible benefits of ...

Experts say semaglutide may be a much-needed treatment option for a liver disease with few current therapies. Ozempic is effective in treating a severe form of liver disease that affects millions ...

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

The ability to not just halt but potentially reverse this scarring process could transform how we approach advanced liver disease treatment. Participants receiving semaglutide experienced an ...

“Thus, semaglutide treatment addressed the primary pathogenic driver of MASH. The drug also provided a holistic therapeutic approach to both liver disease and associated cardiometabolic illnesses.

In this randomized controlled trial, oral semaglutide significantly reduced the risk of adverse cardiovascular events in ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...